Movers & Shakers - Spark Newswire

2 minute read

TerrAscend & Other Marijuana Players Just Made Some Key Exec Changes You Should Know About

September 22, 1:56 PM

TerrAscend Names New President Of Northeast Region TerrAscend Corp. (OTCQX: TRSSF) has tapped Karim Bouaziz to serve as president of the Northeast region.

CANN

2 minute read

Former Crime Analyst To Lead Michigan Cannabis Agency & Latest Key Executive Changes In Marijuana Space

By Jelena Martinovic

September 17, 5:29 PM

Former Crime Analyst To Lead Michigan Cannabis Agency

CGC

1 minute read

Eloxx Shares Plummet As Mid-Stage Cystic Fibrosis Study Results Miss Efficacy Endpoints

By Ragothaman Srinivasan

September 14, 4:45 PM

Eloxx Pharmaceuticals (NASDAQ: ELOX) announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation.

ELOX

2 minute read

GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate

By Ragothaman Srinivasan

September 13, 5:18 PM

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GENFIT’s (NASDAQ: GNFT) drug candidate GNS5611 (ezurpimtrostat) for the treatment of cholangiocarcinoma.

GNFT

1 minute read

Conformis Shares Shoot Higher Following FDA Clearance For Actera Hip System

By Ragothaman Srinivasan

September 13, 4:58 PM

Conformis (NASDAQ: CFMS) has received 510(k) clearance from the U.S. Food and Drug Administration for its Actera Hip System. Actera utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.

CFMS

1 minute read

BioLineRx Seeks FDA Nod For Stem Cell Mobilization Candidate

By Ragothaman Srinivasan

September 12, 3:01 PM

BioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for multiple myeloma patients.

BLRX

2 minute read

Kanye West’s Feud With Adidas And Gap Heats Up: What’s On The Line For Him And The Companies

By Robert Kuczmarski

September 9, 6:47 PM

In 2016, Kanye West's apparel brand Yeezy partnered with Adidas AG - ADR (OTCQX: ADDYY) for Adidas + Kanye West to manufacture footwear, apparel and accessories.

ADDYY

1 minute read

Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022

By Ragothaman Srinivasan

September 9, 4:57 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.

SPPI

1 minute read

Rhythm Secures European Commission Marketing Authorization For Genetic Disease Candidate

By Ragothaman Srinivasan

September 6, 5:11 PM

The European Commission (EC) has expanded the marketing authorization for Rhythm’s (NASDAQ: RYTM) lead drug product IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age an

RYTM

2 minute read

Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study

By Ragothaman Srinivasan

September 6, 9:58 AM

Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA).

ISEE